Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Durable responses after CD19 CAR-T plus ibrutinib in CLL

Alexandre Hirayama • 20 Jun 2019
ICML 2019
Chronic Lymphocytic Leukemia Leukemia CAR-T Ibrutinib

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses responses after CD19-specific CAR T-cell therapy with concurrent ibrutinib in patients with chronic lymphocytic leukemia (CLL) after prior ibrutinib failure. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Alexandre Hirayama

0:59
Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy
Alexandre Hirayama • 2 Jul 2019
1:31
Recent publication on the impact of response to lymphodepletion on PFS in NHL
Alexandre Hirayama • 20 Jun 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals